	<u>.</u>	09-18-199	8	Attorney Docket No. 015542-0)02400U		
	FORM PTO-1595 (Rev. 6-93)		≀ SHEET	U.S. DEPARTMENT OF COM Patent and Trademark	MERCE Office		
Q?	To the Honorable Asst. Commiss. 1. Name of conveying party(ies): CYTOVEN	100832668	2. Name and address	of receiving party(ies): RAN, INC.			
S	Additional name(s) of conveying party(les) attached? Yes X No 3. Nature of conveyance: X Assignment Merger Security Agreement Change of Name Other:		Internal Address: Suit	e 530 o o .s	09/01/9		
(me)			Street Address: 10230 N.E. Points Drive				
	Execution Date: January 16, 19	98	Additional name(s) & address(es) attached? Yes X No				
	4. Application number(s) or patent number(s). If this document is being filed together with a new applicat A. Patent Application No.(s) 08/686,004; 08/144,779; 08/484,511; 08/415,099; 08/486,044; 08/482,121; 08/450,904; 08/452,411; 08/452,077; 08/452,061; 08/614,764		B. Patent No.(s) 5,538,951				
	Additional numbers attached? Yes X No						
	5. Name and address of party to whom correspondence concerning document should be mailed: Name: Susan K. Faris TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834 (415) 576-0200		6. Total number of applications and patents involved: 12 7. Total fee (37 CFR 3.41):				
; ; 0'9/ 01L	17/1998 JSHABAZZ 00000068 201430 09: FC:581 40.00 CH	144960	8. Deposit account number: 20-1430				
	DO NOT USE THIS SPACE						
	9. Statement and signature. To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. Susan K. Faris Name of Person Signing Atty. Reg. No. P41,739 Total number of pages including cover sheet, attachments, and document: 5 10. Change Correspondence Address to that of Part 5? X Yes No						
	OMB No. 0651-0011 (exp. 4/94)						
	Mail documents to be recorded with required cov	ver sheet information to: Asst. Comm Box A	stach this portion sissioner for Patents Assignments on, D.C. 20231				
	washington, u.c. 20231						

F:\DATA\P5\PTOD\JHD\83330.1

SCHEDULE A

TITLE	APPLICATION SERIAL NO.	DATE FILED	PATENT NO.
METHODS OF IDENTIFYING CYTOMEDINES, COMPOSITIONS, AND USES THEREOF	08/686,004	July 25, 1996	
PHARMACEUTICAL LYSINE- CONTAINING POLYPEPTIDE COMPOSITIONS	08/144,779	October 28, 1993	
PHARMACEUTICAL LYSINE- CONTAINING POLYPEPTIDE COMPOSITIONS AND USES THEREOF	08/484,511	June 7, 1995	
PHARMACEUTICAL PREPARATION FOR THE THERAPY OF IMMUNE DEFICIENCY CONDITIONS	08/337,341	November 10, 1994	5,538,951
PHARMACEUTICAL DIPEPTIDE COMPOSITIONS AND METHODS OF USE	08/415,099	March 31, 1995	
PHARMACEUTICAL PREPARATION FOR THE THERAPY OF IMMUNE DEFICIENCY CONDITIONS	08/486,044	June 7, 1995	
PHARMACEUTICAL PREPARATION FOR THE THERAPY OF IMMUNE DEFICIENCY CONDITIONS	08/482,121	June 7, 1995	

SCHEDULE A (cont.)

PHARMACEUTICAL DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF: IMMUNODEPRESSANTS	08/450,904	May 26, 1995
METHODS FOR NORMALIZING NUMBERS OF LYMPHOCYTES	08/452,411	May 26, 1995
PHARMACEUTICAL DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF: SYSTEMIC TOXICITY	08/452,077	May 26, 1995
METHOD FOR TREATMENT OF PURULENT INFLAMMATORY DISEASE	08/452,061	May 26, 1995
PHARMACEUTICAL ANGIOSTATIC DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF	08/614,764	March 13, 1996

ASSIGNMENT OF PATENTS AND PATENT APPLICATIONS

This Assignment is between CYTOVEN, a joint venture formed as a partnership under Washington law, the address of which is 10230 N.E. Points Drive, Suite 530, Kirkland, Washington, and CYTRAN, INC., a Washington corporation, the address of which is 10230 N.E. Points Drive, Suite 530, Kirkland Washington.

RECITALS

On December 2, 1994, CYTRAN, INC., as a result of a merger of CYTOCORP, INC., a Washington Corporation, and CYTRAN, INC., acquired the interest of CYTOCORP, INC. in a joint venture named CYTOVEN. KMC, INC., a Washington corporation was the other partner in the joint venture, which was a general partnership under Washington law. Among the assets of CYTOVEN are the Patents and Patent Applications listed in SCHEDULE A.

On December 31, 1996, KMC, INC. sold its interest in the joint venture, including its share of the assets held by the joint venture, to CYTRAN, INC. for good and valuable consideration. This sale acted under Washington Corporation Law to dissolve the general partnership of CYTOVEN, (RCW § 25.04.310(3)). As indicated in a purchase agreement, the intent of the parties was to transfer all assets of CYTOVEN to CYTRAN, INC.

To wind up its affairs, CYTOVEN seeks to assign all U.S. Patents and Patent Applications in which it is the owner to CYTRAN, INC. Authority for the partnership to act in winding up its affairs after dissolution of the partnership is found in RCW § 25.04.300.

AGREEMENT

CYTOVEN hereby assigns to CYTRAN, INC. all right, title and interest in and to U.S. Letters Patents, and Patent Applications listed in SCHEDULE A in and to any inventions disclosed therein; in and to any Letters Patent and Registrations which may hereafter be granted on the same in the United States; and to claim the priority from the Patents and Patent Applications as provided for by the laws of the United States. The right, title and interest is to be held and enjoyed by CYTRAN, INC. and CYTRAN, INC.'s successors and assigns as fully and exclusively as it would have been held and enjoyed by CYTOVEN had this assignment not been made, for the full term of any Letters

Patent which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

IN TESTIMONY WHEREOF, this Assignment is executed this 16th.

CYTOVEN

BY CYTRAN, INC.

Peter Spurging
Its Vice President

STATE OF

WASHINGTON)

)ss.

COUNTY OF

KING

On January 16, 1998, before me, Mike E. Brandeberry, a Notary Public, personally appeared Peter Spurging, personally known to me (or proved to me on the basis of satisfactory evidence) to be the person whose name is subscribed to the within instrument and acknowledged to me that he executed the same in his authorized capacity, and that by his signature on the instrument the person, or the entity upon behalf of which the person acted, executes the instrument.

WITNESS my hand and official seal.

Signature

Mike E. Brandeberry

My commission expires: 5/27/2001

RECORDED: 09/01/1998

H:\SHARE\015542\002400\ASSIGNME.005